NCT02425306 2023-10-30
Mel63; CHAMP
University of Virginia
Phase 1/2 Terminated
Clinical Trials
6 trialsNCT00145158 2022-10-10
Immunization With 8 Peptides Mixed With CpG 7909 or Montanide ISA51 in Patients With Metastatic Cutaneous Melanoma
Ludwig Institute for Cancer Research
Phase 1/2 Terminated
NCT00365937 2019-03-06
Immunization of Disease-Free Melanoma Patients With Different HLA-A2 Peptides
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Phase 1/2 Terminated
NCT00000105 2017-11-29
Vaccination With Tetanus and KLH to Assess Immune Responses.
Masonic Cancer Center, University of Minnesota
Terminated
NCT00184067 2014-05-21
Continuation Booster Trial After a Vaccine Combining Tyrosinase/GP100/MART-1 Peptides Emulsified With Montanide ISA 51 With or Without GM-CSF for Patients With Melanoma
University of Southern California
Phase 2 Terminated
NCT00678509 2009-12-29
Histocompatibility Leukocyte Antigen (HLA)-A*2402 Restricted Peptide Vaccine Therapy in Patients With Breast Cancer
Tokyo University
Phase 1/2 Terminated